Logo image of BIIB

BIOGEN INC (BIIB) Stock Price, Quote, News and Overview

NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD

116.49  -2.12 (-1.79%)

After market: 116.49 0 (0%)

BIIB Quote, Performance and Key Statistics

BIOGEN INC

NASDAQ:BIIB (4/21/2025, 8:00:01 PM)

After market: 116.49 0 (0%)

116.49

-2.12 (-1.79%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High238
52 Week Low110.04
Market Cap17.05B
Shares146.37M
Float145.56M
Yearly DividendN/A
Dividend YieldN/A
PE7.07
Fwd PE7.24
Earnings (Next)05-01 2025-05-01/bmo
IPO09-17 1991-09-17


BIIB short term performance overview.The bars show the price performance of BIIB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

BIIB long term performance overview.The bars show the price performance of BIIB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of BIIB is 116.49 USD. In the past month the price decreased by -17.32%. In the past year, price decreased by -44.24%.

BIOGEN INC / BIIB Daily stock chart

BIIB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 16.81 301.01B
AMGN AMGEN INC 13.81 147.14B
GILD GILEAD SCIENCES INC 22.63 130.06B
VRTX VERTEX PHARMACEUTICALS INC 1646.62 122.76B
REGN REGENERON PHARMACEUTICALS 12.3 61.38B
ARGX ARGENX SE - ADR 320.27 36.37B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.28B
ONC BEIGENE LTD-ADR N/A 24.70B
BNTX BIONTECH SE-ADR N/A 24.47B
NTRA NATERA INC N/A 19.23B
SMMT SUMMIT THERAPEUTICS INC N/A 18.60B
UTHR UNITED THERAPEUTICS CORP 11.55 12.77B

About BIIB

Company Profile

BIIB logo image Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS 02142 US

CEO: Michel Vounatsos

Employees: 7570

Company Website: https://www.biogen.com/

Investor Relations: https://investors.biogen.com

Phone: 17814642000

BIOGEN INC / BIIB FAQ

What is the stock price of BIOGEN INC today?

The current stock price of BIIB is 116.49 USD. The price decreased by -1.79% in the last trading session.


What is the ticker symbol for BIOGEN INC stock?

The exchange symbol of BIOGEN INC is BIIB and it is listed on the Nasdaq exchange.


On which exchange is BIIB stock listed?

BIIB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIOGEN INC stock?

43 analysts have analysed BIIB and the average price target is 200.75 USD. This implies a price increase of 72.33% is expected in the next year compared to the current price of 116.49. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOGEN INC worth?

BIOGEN INC (BIIB) has a market capitalization of 17.05B USD. This makes BIIB a Large Cap stock.


How many employees does BIOGEN INC have?

BIOGEN INC (BIIB) currently has 7570 employees.


What are the support and resistance levels for BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a support level at 115.17 and a resistance level at 116.89. Check the full technical report for a detailed analysis of BIIB support and resistance levels.


Is BIOGEN INC (BIIB) expected to grow?

The Revenue of BIOGEN INC (BIIB) is expected to decline by -4.32% in the next year. Check the estimates tab for more information on the BIIB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOGEN INC (BIIB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOGEN INC (BIIB) stock pay dividends?

BIIB does not pay a dividend.


When does BIOGEN INC (BIIB) report earnings?

BIOGEN INC (BIIB) will report earnings on 2025-05-01, before the market open.


What is the Price/Earnings (PE) ratio of BIOGEN INC (BIIB)?

The PE ratio for BIOGEN INC (BIIB) is 7.07. This is based on the reported non-GAAP earnings per share of 16.47 and the current share price of 116.49 USD. Check the full fundamental report for a full analysis of the valuation metrics for BIIB.


What is the Short Interest ratio of BIOGEN INC (BIIB) stock?

The outstanding short interest for BIOGEN INC (BIIB) is 2.56% of its float. Check the ownership tab for more information on the BIIB short interest.


BIIB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BIIB Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BIIB. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIIB Financial Highlights

Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 16.47. The EPS increased by 9.22% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.87%
ROA 5.82%
ROE 9.76%
Debt/Equity 0.27
Chartmill High Growth Momentum
EPS Q2Q%4.24%
Sales Q2Q%2.87%
EPS 1Y (TTM)9.22%
Revenue 1Y (TTM)-1.62%

BIIB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to BIIB. The Buy consensus is the average rating of analysts ratings from 43 analysts.

For the next year, analysts expect an EPS growth of -2.34% and a revenue growth -4.32% for BIIB


Ownership
Inst Owners94.24%
Ins Owners0.12%
Short Float %2.56%
Short Ratio2.39
Analysts
Analysts74.42
Price Target200.75 (72.33%)
EPS Next Y-2.34%
Revenue Next Year-4.32%